Home » Customer Testimonials » Kincell Bio

Kincell Bio.

This leading CDMO delivering end-to-end CGT development, from early clinical programs through commercial supply. In March 2025, they brought IRO® into their facility to assess how it could expand their technology offering, increase manufacturing flexibility, and support clients as programs transition toward commercial readiness.

  • "Given IRO's ability to provide continuous monitoring of cell culture, its automated and sterile cell/ culture additions, as well as its demonstrated efficiency with producing large amount of CAR+ T-cells, it is [our] Process Development opinion that the ORI IRO bioreactor has potential to streamline the T-cell Therapy space"

Webinar

Learn more about the financial and operational realities shaping the path from early development to commercial manufacturing in CGT, featuring Dr. Bruce Thompson from Kincell Bio. This event took place in November 2025.

Learn more

Event

Explore how partnerships, modular platforms, and advanced manufacturing are shaping the future of cell and gene therapy, featuring Dr. Bruce Thompson from Kincell Bio. This event took place in September 2025.

Learn more